Macular Society Newsletter

Here’s the latest from the Macular society – their newsletter headlines are all below – to read the full story on all of them, view the full newsletter here:

Welcome to your May e-newsletter. I hope you are well and looking forward to a once-in-a-lifetime weekend as the new King is crowned.

As always, there’s lots of exciting updates to share with you. Firstly, the topic that everyone with age-related macular degeneration (AMD) is talking about – a new treatment for dry AMD. Consultant ophthalmologist Ian Pearce will be sharing everything he knows about the new drug in one of our webinars from the experts in macular disease.

You continue to inspire us in everything you do and this month we’re delighted to feature the remarkable efforts of our lovely supporter Judy, who is proving to herself and others that anything is possible, no matter your age – go Judy! Thank you, as ever, for your unwavering support to help Beat Macular Disease.

Syfovre – the first treatment for dry AMD
We’re delighted to welcome consultant ophthalmologist and retinal surgeon Ian Pearce to our My Macular and Me webinar this month. Ian will discuss the biggest news in treatment for macular disease – a new drug for dry AMD. Syfovre was approved for use in the US earlier this year. Ian will look into the results from the clinical trials in more detail, as well as answer your questions.

Do you suffer from pain after your eye injection?
While many people don’t experience any problems from their regular eye injections, unfortunately there are others who suffer pain or discomfort in the hours following the treatment. So why do some people experience pain and how can you manage it?

Laser treatment for diabetic macular oedema (DMO)
For our second My Macular and Me webinar in May, we are joined by professor of ophthalmology, Noemi Lois, as she talks about the positive results of a recent trial to test a brand new laser treatment for patients with DMO.

Biosimilars – the cheaper drugs for macular degeneration
As patents for existing drugs to treat wet AMD and DMO expire, cheaper drugs – known as biosimilars – are becoming available to patients. Professor Richard Gale tells us more about what this means for patients and ophthalmology services.

“You have to remind yourself what you can achieve”
Judy, vowed never to climb the O2. But, at the age of 79, she was determined to show us all what we can achieve if we put our minds to it. We are in awe of Judy’s achievement!

Young Harry raises awareness of macular disease with Warhammer
Twelve-year-old Warhammer fanatic, Harry has organised a fundraising tournament in memory of his beloved late grandad, Norman, to raise awareness of macular disease and support others with the condition, after seeing the impact it had on his life.

Volunteers needed to test home-monitoring app
OKKO Health, a digital health company which is developing a mobile app to allow you to monitor your vision from home, is looking for volunteers. If you have AMD and would like to help test the smartphone app, which uses software similar to that of a video game to assess visual health, they’d love to hear from you.

Listen to the experts in our new podcasts
We’re excited to announce we are rolling out a new series of podcasts to bring you closer to the experts. Every month we are joined by a range of speakers who discuss the latest in treatments, research and technology.

Join us and Beat Macular Disease
Join as a member for a six-month free trial and receive your exclusive members-only magazine packed with research updates, expert advice and tips for living with macular disease. Sign up for your membership today!

Advice and Information Service  0300 3030 111

help@macularsociety.org

View the full newsletter here